▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #4178 by analyst upside · 2026-06-29
MRNA
Moderna, Inc.
Healthcare · Market Cap $27B · P/E 0x
ANALYST PRICE TARGET
-34.2%
implied upside to consensus target
Current Price $67.27
Consensus Target $44.25
Bull Target $77.0
Bear Target $22.0
Analysts Covering 20
ANALYST CONSENSUS - HOLD
Strong Buy
2
Buy
2
Hold
14
Sell
2
52-Week Low $22.28
52-Week High $69.28
YTD Return +118.0%
FUNDAMENTALS
Market Cap $27B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-8.14
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $2.2B
Profit Margin -143.6%
52-WEEK RANGE
52-Week Low $22.28
52-Week High $69.28
Current Price $67.27
Bear Target $22.0
Bull Target $77.0
● Now $67.27 ● Target $44.25
TRADING DATA
Avg Volume 7.2M
YTD Return +118.0%
Analyst Count 20
Consensus Hold
Upside to Target -34.2%
Last Updated 2026-06-29

ANALYST SUMMARY

Moderna, Inc. (MRNA) is currently trading at $67.27 with a Wall Street consensus price target of $44.25, which is 34.2% below the current price over the next 12 months. 20 analysts currently cover MRNA, with a consensus rating of Hold - 20% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $77.0, while the most cautious has a target of $22.0.

MRNA operates in the Healthcare sector with a market capitalisation of $27B. The stock is up 118.0% year-to-date and is currently trading near the upper end of its 52-week range of $22.28 – $69.28.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ILMN -14.1%
Illumina, Inc.
$27B · P/E 32.0x · Hold
INCY -2.7%
Incyte Corporation
$23B · P/E 16.1x · Hold
BIIB +2.0%
Biogen Inc.
$32B · P/E 23.3x · Hold
MTD +3.8%
Mettler-Toledo International Inc.
$26B · P/E 29.7x · Buy
DGX +6.5%
Quest Diagnostics Incorporated
$23B · P/E 23.2x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for MRNA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

B of A Securities — Reiterated
Underperform → Underperform 2026-06-08 Building track record
UBS — Reiterated
Neutral → Neutral 2026-05-04 33% win rate (6 calls)
Goldman Sachs — Reiterated
Neutral → Neutral 2026-05-04 Building track record
Evercore ISI Group — Reiterated
In-Line → In-Line 2026-05-04 Building track record
RBC Capital — Reiterated
Sector Perform → Sector Perform 2026-05-04 Building track record
Barclays — Reiterated
Equal-Weight → Equal-Weight 2026-04-02 Building track record
Piper Sandler — Reiterated
Overweight → Overweight 2026-02-23 14% win rate (7 calls)
Goldman Sachs — Reiterated
Neutral → Neutral 2026-02-17 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
39
out of 100
Coverage depth
23/30
Consensus clarity
14/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →